Difference between revisions of "Lee:Publications"

From OpenWetWare
Jump to: navigation, search
Line 15: Line 15:

Revision as of 01:46, 16 July 2010

Home        Research        Lab Members        Publications        Transporters        Proteasomes        PK/PD/PGx        JC        Links        Internal        Contact       


  1. Lee W, Patel JH, and Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs. 2009 Sep;18(9):1351-64. DOI:10.1517/13543780903179286 | PubMed ID:19642951 | HubMed [1]
  2. Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, Senturk E, Calcutt MW, and Rizvi NA. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol. 2010 Apr;65(5):833-8. DOI:10.1007/s00280-009-1088-4 | PubMed ID:19672598 | HubMed [2]
All Medline abstracts: PubMed | HubMed


  1. Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, and El-Rifai W. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res. 2008 Dec 15;68(24):10315-23. DOI:10.1158/0008-5472.CAN-08-1984 | PubMed ID:19074900 | HubMed [1]
  2. Lockhart AC, Harris E, LaFleur BJ, Merchant NB, Washington MK, Resnick MB, Yeatman TJ, Lee W. Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol:1-7(2008) [2]
  3. Wade Calcutt M, Lee W, Puzanov I, Rothenberg ML, and Hachey DL. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom. 2008 Jan;43(1):42-52. DOI:10.1002/jms.1268 | PubMed ID:17683023 | HubMed [3]
All Medline abstracts: PubMed | HubMed


  1. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, and Kim RB. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007 Mar;81(3):362-70. DOI:10.1038/sj.clpt.6100056 | PubMed ID:17215845 | HubMed [1]
  2. Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, and Kim RB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol. 2007 Aug;21(8):1769-80. DOI:10.1210/me.2007-0025 | PubMed ID:17519356 | HubMed [2]
  3. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Stein CM, and Kim RB. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007 Aug;17(8):647-56. DOI:10.1097/FPC.0b013e3280ef698f | PubMed ID:17622941 | HubMed [3]
All Medline abstracts: PubMed | HubMed


  1. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806. DOI:10.1053/j.gastro.2006.02.034 | PubMed ID:16697742 | HubMed [1]
  2. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, and Kim RB. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem. 2005 Mar 11;280(10):9610-7. DOI:10.1074/jbc.M411092200 | PubMed ID:15632119 | HubMed [2]
  3. Lee W, Lockhart AC, Kim RB, and Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist. 2005 Feb;10(2):104-11. DOI:10.1634/theoncologist.10-2-104 | PubMed ID:15709212 | HubMed [3]
  4. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, and Kim RB. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. DOI:10.1124/dmd.104.003244 | PubMed ID:15716364 | HubMed [4]
  5. Lee W and Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-66. DOI:10.1146/annurev.pharmtox.44.101802.121856 | PubMed ID:14744242 | HubMed [5]
  6. Ho RH, Leake BF, Roberts RL, Lee W, and Kim RB. Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004 Feb 20;279(8):7213-22. DOI:10.1074/jbc.M305782200 | PubMed ID:14660639 | HubMed [6]
  7. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, Schuetz EG, and Kim RB. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med. 2003 Feb;9(2):220-4. DOI:10.1038/nm815 | PubMed ID:12514743 | HubMed [7]
  8. Lee WI and Fung HL. Mechanism-based partial inactivation of glutathione S-transferases by nitroglycerin: tyrosine nitration vs sulfhydryl oxidation. Nitric Oxide. 2003 Mar;8(2):103-10. PubMed ID:12620373 | HubMed [8]
  9. Lee WI, Xu Y, Fung SM, and Fung HL. eNOS-dependent vascular interaction between nitric oxide and calcitonin gene-related peptide in mice: gender selectivity and effects on blood aggregation. Regul Pept. 2003 Jan 31;110(2):115-22. PubMed ID:12527144 | HubMed [9]
  10. Wang EQ, Lee WI, Brazeau D, and Fung HL. cDNA microarray analysis of vascular gene expression after nitric oxide donor infusions in rats: implications for nitrate tolerance mechanisms. AAPS PharmSci. 2002;4(2):E10. DOI:10.1208/ps040210 | PubMed ID:12102619 | HubMed [10]
  11. Wang EQ, Lee WI, and Fung HL. Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. Br J Pharmacol. 2002 Jan;135(2):299-302. DOI:10.1038/sj.bjp.0704532 | PubMed ID:11815364 | HubMed [11]
  12. Tabrizi-Fard MA, Lee WI, and Fung HL. Differential interactions of nitric oxide donors with rat oxyhemoglobin. Biochem Pharmacol. 1999 Aug 15;58(4):671-4. PubMed ID:10413305 | HubMed [12]
  13. Park JH, Lee WI, Yoon WH, Park YD, Lee JS, and Lee MG. Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. Biopharm Drug Dispos. 1998 Sep;19(6):357-64. PubMed ID:9737816 | HubMed [13]
  14. Kwak MK, Lee WI, Kim ND, and Lee MG. Metabolic changes of acetaminophen after intravenous administration to rats pretreated with 2-(allylthio)pyrazine. Biopharm Drug Dispos. 1998 May;19(4):273-7. PubMed ID:9604128 | HubMed [14]
  15. Lee WI, Yoon WH, Shin WG, Song IS, and Lee MG. Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. Biopharm Drug Dispos. 1997 Dec;18(9):753-67. PubMed ID:9429740 | HubMed [15]
  16. Yoon EJ, Lee WI, Shim HJ, Lee SD, Kim WB, Yang J, and Lee MG. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Biopharm Drug Dispos. 1996 Jul;17(5):373-420. DOI:10.1002/(SICI)1099-081X(199607)17:5<373::AID-BDD373>3.0.CO;2-U | PubMed ID:8830976 | HubMed [16]
  17. Lee WI, Yoon WH, Park JH, Lee JW, Shim CK, and Lee MG. Factors influencing the protein binding of YH-439 using an equilibrium dialysis technique. A new hepatoprotective agent. Biopharm Drug Dispos. 1995 Dec;16(9):775-89. PubMed ID:8580401 | HubMed [17]
  18. Hwang SJ, Park JM, Lee WI, Kim ON, and Lee MG. The effect of water deprivation on the pharmacokinetics of methotrexate in rats. Biopharm Drug Dispos. 1995 Apr;16(3):245-50. PubMed ID:7787136 | HubMed [18]
  19. Kim EJ, Yoon WH, Lee WI, Kim ON, and Lee MG. The effect of dehydration on the disposition kinetics of propranolol in rats. Biopharm Drug Dispos. 1995 Apr;16(3):251-7. PubMed ID:7787137 | HubMed [19]
All Medline abstracts: PubMed | HubMed